XXXIII Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia

XXXIII Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia 90 ferential Roles for the Coagulation Factors XI and XII in Regulating the Physical Biology of Fibrin. Ann Biomed Eng 2017;45:1328-40. 7. Colucci M, Incampo F, Cannavo A, Menegatti M, Siboni SM, et al. Reduced fibrinolytic resistance in patients with factor XI deficien- cy. Evidence of a thrombin-independent impairment of the throm- bin-activatable fibrinolysis inhibitor pathway. J Thromb Haemost 2016;14:1603-14. 8. von dem Borne PA, Bajzar L, Meijers JC, NesheimME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-ac- tivatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997;99:2323-7. 9. Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost 2013;39:621-31. 10. He R, Chen D, He S. Factor XI: hemostasis, thrombosis, and anti- thrombosis. Thromb Res 2012;129:541-50. 11. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991;325:153-8. 12. Asakai R, Davie EW, Chung DW. Organization of the gene for human factor XI. Biochemistry 1987;26:7221-8. 13. Castaman G, Giacomelli SH, Caccia S, Riccardi F, Rossetti G, et al. The spectrum of factor XI deficiency in Italy. Haemophilia 2014;20:106-13. 14. Gueguen P, ChauvinA, Quemener-Redon S, Pan-Petesch B, Ferec C, et al. Revisiting the molecular epidemiology of factor XI deficiency: nine new mutations and an original large 4qTer deletion in western Brittany (France). Thromb Haemost 2012;107:44-50. 15. Mitchell M, Mountford R, Butler R, Alhaq A, Dai L, et al. Spectrum of factor XI (F11) mutations in the UK population--116 index cases and 140 mutations. Hum Mutat 2006;27:829. 16. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study. Thromb Haemost 1995;73:194-202. 17. Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifes- tations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement ther- apy. Haemophilia 2006;12:490-3. 18. Gailani D, Lasky NM, Broze GJ, Jr. A murine model of factor XI deficiency. Blood Coagul Fibrinolysis 1997;8:134-44. 19. Renne T, Oschatz C, Seifert S, Muller F,Antovic J, et al. Factor XI defi- ciency in animal models. J Thromb Haemost 2009;7(Suppl 1):79-83. 20. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000;342:696-701. 21. Eichinger S, Schonauer V, Weltermann A, Minar E, Bialonczyk C et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004;103:3773-6. 22. Yang L, Sun MF, Gailani D, Rezaie AR. Characterization of a hep- arin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins anti- thrombin and C1-inhibitor. Biochemistry. 2009;48:1517-24. 23. Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated with an increased odds ratio for cere- brovascular events. Am J Clin Pathol 2006;126:411-5. 24. Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, et al. Factor XI defi- ciency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 2017;129:1210-5. 25. Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, et al. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 2011;105:269-73. 26. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008;111:4113-7. 27. Girolami A, Peroni E, Girolami B, Ferrari S, Lombardi AM. Con- genital factor XI and factor VII deficiencies assure an apparent oppo- site protection against arterial or venous thrombosis: An intriguing observation. Hematology 2016;1-4. 28. Salomon O, Steinberg DM, Dardik R, Rosenberg N, Zivelin A, et al. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 2003;1:658-61. 29. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost 2002;87:774-6. 30. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, et al. Defec- tive thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202:271-81. 31. Wang X, Smith PL, Hsu MY, Gailani D, Schumacher WA, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 2006;4:1982-8. 32. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005;3:695-702. 33. Baird TR, Gailani D, Furie B, Furie BC. Factor XI deficient mice have reduced platelet accumulation and fibrin deposition after laser injury.Blood 2004;104:66a-a. 34. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, et al. Tar- geting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006;203:513-8. 35. Tucker EI, Gailani D, Hurst S, Cheng Q, Hanson SR, et al. Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. J Infect Dis 2008;198:271-4. 36. Chan JC, Ganopolsky JG, Cornelissen I, SuckowMA, Sandoval-Coo- per MJ, et al. The characterization of mice with a targeted combined deficiency of protein c and factor XI. Am J Pathol 2001;158:469-79. 37. Lin J, Deng H, Jin L, Pandey P, Quinn J, et al. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. J Med Chem 2006;49:7781-91. 38. Deng H, Bannister TD, Jin L, Babine RE, Quinn J, et al. Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhib- itors containing an alpha-ketothiazole arginine. Bioorg Med Chem Lett 2006;16:3049-54. 39. Schumacher WA, Seiler SE, Steinbacher TE, Stewart AB, Bostwick JS, et al. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol 2007;570:167-74. 40. Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 2009;206:2381-95. 41. GruberA, Hanson SR. Factor XI-dependence of surface- and tissue fac- tor-initiated thrombus propagation in primates. Blood 2003;102:953-5. 42. Takahashi M, Yamashita A, Moriguchi-Goto S, Sugita C, Matsu- moto T, et al. Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis. Thromb Res 2010;125:464-70. 43. Yamashita A, Nishihira K, Kitazawa T,Yoshihashi K, Soeda T, et al. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost 2006;4:1496-501. 44. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010;116:3981-9. 45. Lowenberg EC, Meijers JC, Monia BP, Levi M. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost 2010;8:2349-57.